Page last updated: 2024-09-03

marimastat and prinomastat

marimastat has been researched along with prinomastat in 20 studies

Compound Research Comparison

Studies (marimastat)	Trials (marimastat)	Recent Studies (post-2010) (marimastat)	Studies (prinomastat)	Trials (prinomastat)	Recent Studies (post-2010) (prinomastat)
215	28	53	97	5	18

Protein Interaction Comparison

Protein	Taxonomy	prinomastat (IC50)
Interstitial collagenase	Homo sapiens (human)	0.0209
72 kDa type IV collagenase	Homo sapiens (human)	0.0005
Stromelysin-1	Homo sapiens (human)	0.0022
Matrilysin	Homo sapiens (human)	0.0723
Matrix metalloproteinase-9	Homo sapiens (human)	0.0007
Neutrophil collagenase	Homo sapiens (human)	0.0005
Collagenase 3	Homo sapiens (human)	0.0008
Melatonin receptor type 1A	Gallus gallus (chicken)	0.0049
Melatonin receptor type 1C	Gallus gallus (chicken)	0.0049
Matrix metalloproteinase-14	Homo sapiens (human)	0.0003
Melatonin receptor type 1B	Gallus gallus (chicken)	0.0049
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	0.022

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (15.00)	18.2507
2000's	12 (60.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	5 (25.00)	2.80

Authors

Authors	Studies
Barlaam, B; Bird, TG; Campbell, D; Foster, SJ; Lambert-Van Der Brempt, C; Maciewicz, R	1
Barta, TE; Becker, DP; Bedell, LJ; De Crescenzo, GA; McDonald, JJ; Munie, GE; Rao, S; Shieh, HS; Stegeman, R; Stevens, AM; Villamil, CI	1
Atassi, G; Bertrand, M; Bonnet, J; Casara, P; Chollet, AM; Le Diguarher, T; Murray, L; Pierré, A; Sabatini, M; Tucker, GC	1
Barta, TE; Becker, DP; Bedell, LJ; De Crescenzo, GA; McDonald, JJ; Mehta, P; Munie, GE; Villamil, CI	1
Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK	1
Bertrand, M; Casara, P; Chollet, AM; Guilbaud, N; Hennig, P; Le Diguarher, T; Pierré, A; Raimbaud, E; Sabatini, M; Tucker, GC	1
DasGupta, S; Giridhar, R; Murumkar, PR; Yadav, MR	1
Charton, J; Dassonneville, S; Deprez, B; Deprez-Poulain, R; Flipo, M; Hocine, A	1
Nelson, NJ	1
Hande, KR; Nelson, AR; Rothenberg, ML	1
Fingleton, B; Matrisian, LM; Nelson, AR; Rothenberg, ML	1
Nakajima, M	1
Eckhardt, SG; Hidalgo, M	1
Bergen, M; Eckhardt, SG; Hidalgo, M; Holden, SN; Pierson, AS	1
Howes, JM; Laing, GD; Theakston, RD	1
Bourke, LA; Chowdhury, A; Dobson, JS; Fry, BG; Soria, R; Zdenek, CN	1
Carter, R; Chowdhury, A; Fry, BG; Lewin, MR; Zdenek, CN	1
Carter, RW; Casewell, NR; Chowdhury, A; Fry, BG; Lewin, MR	1
Aldridge, M; Carter, R; Chowdhury, A; Fry, BG; Lewin, MR; Soria, R	1
Afshar, S; Bahreini, F; Mortezapour, M; Najafi, R; Tapak, L	1

Reviews

4 review(s) available for marimastat and prinomastat

Article	Year
Current perspective of TACE inhibitors: a review. Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2 Topics: ADAM Proteins; ADAM17 Protein; Animals; Arthritis, Rheumatoid; Enzyme Inhibitors; Humans; Models, Molecular; Neoplasms; Structure-Activity Relationship	2009
[Matrix metalloproteinase inhibitors]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2000, Volume: 45, Issue:6 Suppl Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Metastasis; Organic Chemicals; Phenylalanine; Thiophenes	2000
Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute, 2001, Feb-07, Volume: 93, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes	2001
Therapeutic angiogenesis inhibitors in the treatment of cancer. Advances in internal medicine, 2001, Volume: 47 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Collagen; Endostatins; Endothelial Growth Factors; Enzyme Inhibitors; Estradiol; Humans; Hydroxamic Acids; Lymphokines; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Peptide Fragments; Protein-Tyrosine Kinases; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001

Other Studies

16 other study(ies) available for marimastat and prinomastat

Article	Year
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. Journal of medicinal chemistry, 1999, Nov-18, Volume: 42, Issue:23 Topics: ADAM Proteins; ADAM17 Protein; Administration, Oral; Animals; Callithrix; Humans; Hydroxamic Acids; Metalloendopeptidases; Protease Inhibitors; Quinazolines; Succinates; Tumor Necrosis Factor-alpha	1999
Synthesis and activity of selective MMP inhibitors with an aryl backbone. Bioorganic & medicinal chemistry letters, 2000, Dec-18, Volume: 10, Issue:24 Topics: Antineoplastic Agents; Collagenases; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Matrix Metalloproteinase 1; Matrix Metalloproteinase 13; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Models, Molecular; Structure-Activity Relationship	2000
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors. Bioorganic & medicinal chemistry letters, 2001, Feb-12, Volume: 11, Issue:3 Topics: Animals; Antineoplastic Agents; Antirheumatic Agents; Biological Availability; Cartilage; Combinatorial Chemistry Techniques; Drug Stability; Humans; Matrix Metalloproteinase Inhibitors; Mice; Microsomes, Liver; Neoplasm Metastasis; Neoplasms, Experimental; Propionates; Proteoglycans; Structure-Activity Relationship; Substrate Specificity; Tumor Cells, Cultured	2001
Selective, orally active MMP inhibitors with an aryl backbone. Bioorganic & medicinal chemistry letters, 2001, Sep-17, Volume: 11, Issue:18 Topics: Administration, Oral; Animals; Biological Availability; Drug Design; Matrix Metalloproteinase 13; Matrix Metalloproteinase Inhibitors; Piperidines; Protease Inhibitors; Rats; Structure-Activity Relationship; Sulfhydryl Compounds	2001
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. Journal of medicinal chemistry, 2002, Jan-03, Volume: 45, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line; Formamides; Hydroxylamines; Macaca fascicularis; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Mice; Protease Inhibitors; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays	2002
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. Journal of medicinal chemistry, 2003, Aug-28, Volume: 46, Issue:18 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Caco-2 Cells; Cyclopentanes; Humans; In Vitro Techniques; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Melanoma, Experimental; Mice; Microsomes, Liver; Models, Molecular; Molecular Conformation; Neoplasm Metastasis; Permeability; Phthalimides; Protease Inhibitors; Stereoisomerism; Structure-Activity Relationship; Triazines	2003
Hydroxamates: relationships between structure and plasma stability. Journal of medicinal chemistry, 2009, Nov-12, Volume: 52, Issue:21 Topics: Animals; Drug Evaluation, Preclinical; Drug Stability; Esterases; Half-Life; Humans; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Hydroxamic Acids; Plasma; Prodrugs; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship	2009
Inhibitors of angiogenesis enter phase III testing. Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13 Topics: Angiostatins; Animals; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Collagen; Endostatins; Endothelium, Vascular; Humans; Hydroxamic Acids; Metalloendopeptidases; Neovascularization, Pathologic; Organic Chemicals; Peptide Fragments; Phenylbutyrates; Plasminogen	1998
New drugs on the horizon: matrix metalloproteinase inhibitors. Stem cells (Dayton, Ohio), 1999, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Azepines; Biphenyl Compounds; Humans; Hydroxamic Acids; Metalloendopeptidases; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Thiophenes	1999
Matrix metalloproteinases: biologic activity and clinical implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 1; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals	2000
Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. Toxicon : official journal of the International Society on Toxinology, 2007, Volume: 49, Issue:5 Topics: Animals; Biphenyl Compounds; Chelating Agents; Chromatography, Gel; Chromatography, Liquid; Edetic Acid; Egtazic Acid; Ethylenediamines; Evaluation Studies as Topic; Hemorrhage; Hydroxamic Acids; Metalloproteases; Mice; Molecular Structure; Organic Chemicals; Phenylbutyrates; Protein Kinase Inhibitors; Pyrazines; Snake Bites; Statistics, Nonparametric; Sulfonamides; Viper Venoms	2007
Clinical implications of differential procoagulant toxicity of the palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors. Toxicology letters, 2021, Apr-01, Volume: 340 Topics: Animals; Antivenins; Blood Coagulation; Factor X; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Organic Chemicals; Phospholipids; Species Specificity; Viper Venoms; Viperidae	2021
The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra ( Frontiers in immunology, 2021, Volume: 12 Topics: Acetates; Africa; Animals; Antivenins; Enzyme Inhibitors; Hydroxamic Acids; In Vitro Techniques; Indoles; Keto Acids; Naja; Organic Chemicals; Snake Bites; Snake Venoms	2021
Keel venom: Rhabdophis subminiatus (Red-Necked Keelback) venom pathophysiologically affects diverse blood clotting pathways. Toxicon : official journal of the International Society on Toxinology, 2022, Oct-30, Volume: 218 Topics: Animals; Antivenins; Australia; Blood Coagulation; Blood Coagulation Factors; Colubridae; Elapidae; Factor VII; Factor X; Humans; Hydroxamic Acids; Mammals; Organic Chemicals; Prothrombin; Snake Venoms; Unithiol	2022
Extreme Procoagulant Potency in Human Plasma of Venoms from the African Viperid Genera Toxins, 2022, 12-01, Volume: 14, Issue:12 Topics: Africa South of the Sahara; African People; Animals; Antivenins; Enzyme Inhibitors; Humans; Saudi Arabia; Snake Bites; Viper Venoms; Viperidae	2022
Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co-expression network analysis. Computers in biology and medicine, 2023, Volume: 157 Topics: Bevacizumab; Biomarkers; Colorectal Neoplasms; Curcumin; Gene Regulatory Networks; Humans; Matrix Metalloproteinase 9; Microbial Collagenase; MicroRNAs	2023